Name | Calpeptin,N-Benzyloxycarbonyl-L-leucylnorleucinal |
---|---|
Synonyms |
Z-LEU-NLE-CHO
BENZYLOXYCARBONYLLEUCYL-NORLEUCINAL N-Benzyloxycarbonyl-L-leucylnorieucinal Z-Leu-Nle-CHO MFCD00155623 N-CBZ-L-LEUCYL-NORLEUCINAL N-[(benzyloxy)carbonyl]-N-[(2S)-1-oxohexan-2-yl]-L-leucinamide Z-Leu-Nle-H CalpeptinN-Benzyloxycarbonyl-L-leucyl-norleucinal CALPEPTIN Z-LEU-NLE-OH Z-LEU-NORLEUCINAL Carbamic acid, N-[(1S)-1-[[[(1S)-1-formylpentyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester N-BENZYLOXYCARBONYL-L-LEUCYLNORLEUCINAL BENZYLOXYCARBONYLDIPEPTIDYL ALDEHYDE N-benzyloxycarbonyl-L-leucyl-L-norleucinal N-[(Benzyloxy)carbonyl]-N-[(2S)-1-oxo-2-hexanyl]-L-leucinamide |
Description | Calpeptin is a potent, cell penetrating calpain inhibitor, with an ID50 of 40 nM for Calpain I in human platelets[1]. Calpeptin is also an inhibitor of cathepsin K[2]. |
---|---|
Related Catalog | |
Target |
ID50: 40 nM (Calpain I in human platelets)[1]. Cthepsin K[2] |
In Vitro | Calpeptin (0-100 nM, 24 hours) treatment suppresses the proliferation of both WI38 VA13 and IMR90 cells in a dose-dependent manner. Calpeptin (1000 pg/ml, 24 hours) inhibits IL-6-induced cell proliferation of lung fibroblasts[3]. Cell Proliferation Assay[3] Cell Line: WI38 VA13 and IMR90 cells Concentration: 0-100 nM Incubation Time: 24 hours Result: Suppressed the proliferation in a dose-dependent manner. |
In Vivo | Calpeptin with Bleo (0.04 mg/mouse, i.p., 3 times weekly, 28 days) administration significantly inhibits the collagen deposition and increases of calpain activity in the bleomycintreatedmouse lung tissues[3]. Animal Model: C57BL/6 female mice (Eight-week-old)[3]. Dosage: 0.04 mg/mouse. Administration: Intraperitoneally three times weekly for 28 days (together with Bleo). Result: Inhibited the collagen deposition and increase of calpain activity in the bleomycintreatedmouse lung tissues. |
References |
Density | 1.1±0.1 g/cm3 |
---|---|
Boiling Point | 550.7±45.0 °C at 760 mmHg |
Melting Point | 60-75 °C |
Molecular Formula | C20H30N2O4 |
Molecular Weight | 362.463 |
Flash Point | 286.8±28.7 °C |
Exact Mass | 362.220551 |
PSA | 84.50000 |
LogP | 4.37 |
Vapour Pressure | 0.0±1.5 mmHg at 25°C |
Index of Refraction | 1.508 |
Storage condition | -20°C |
Safety Phrases | S24/25 |
---|---|
RIDADR | NONH for all modes of transport |
~79% 117591-20-5 |
Literature: Tavares, Francis X.; Deaton, David N.; Miller, Aaron B.; Miller, Larry R.; Wright, Lois L. Bioorganic and Medicinal Chemistry Letters, 2005 , vol. 15, # 17 p. 3891 - 3895 |
~% 117591-20-5 |
Literature: Bioorganic and Medicinal Chemistry Letters, , vol. 15, # 17 p. 3891 - 3895 |
~% 117591-20-5 |
Literature: Bioorganic and Medicinal Chemistry Letters, , vol. 15, # 17 p. 3891 - 3895 |
Precursor 2 | |
---|---|
DownStream 0 |